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Abstract
Background:  The role of telomerase activation in the expression and/or maintenance of drug
resistance is not clearly understood. Therefore, we investigated the relationships, among the
telomerase activity, telomere length and the expression of multidrug resistance genes in colorectal
cancer cell lines cultivated with anti-cancer drugs.
Methods:  LoVo and DLD-1 cells were continuously grown in the presence of both CDDP and 5-
FU for up to 100 days. Cell proliferation, telomerase activity, telomere length and the expression
of multidrug resistance genes were serially monitored as the PDL increased.
Results:  The expression of multidrug resistance genes tended to increase as the PDL increased.
However, an abnormal aneuploid clone was not detected as far as the cells were monitored by a
DNA histogram analysis. Tumor cells showing resistance to anti-cancer drugs revealed a higher cell
proliferation rate. The telomere length gradually increased with a progressive PDL. The telomerase
activity reached a maximum level at 15 PDL in LoVo cells and at 27 PDL in DLD-1 cells. An increase
in the mRNA expression of the telomerase components, especially in hTERT and in hTR, was
observed at the same PDLs.
Conclusions:  These results suggest that a high telomerase activity and an elongation of telomeres
both appear to help maintain and/or increase drug resistance in colorectal cancer cells. Cancer cells
with long telomeres and a high proliferative activity may thus be able to better survive exposure to
anti-cancer drugs. This is presumably due to an increased chromosome stability and a strong
expression of both mdr-1 and MRP genes.
Background
We often encounter patients with tumors acquiring
multidrug resistance during the course of chemotherapy.
An acceleration of the cancer cell proliferation is one of
the most troublesome problems in actual clinical situa-
tions. The multidrug resistance gene (mdr-1) and multi-
drug resistance-associated protein (MRP) have been
studied in various human tissues [1–3], and they have
been proven to play a central role in the progression of
drug resistance in colorectal cancers. mdr-1 and MRP
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cells and they also frequently exist on abnormal chromo-
somes such as double minute chromosomes [4–6]. How-
ever, the mechanism regarding how these genes stably
exist on abnormal chromosomes of replicated tumor
cells is still not sufficiently understood.
On the other hand, telomere shortening has been report-
ed to be involved in the formation and preservation of
abnormal chromosomes [7]. In addition, once tumor
cells acquire telomerase activity, the telomere length has
been shown to be maintained [8–11]. In such cases, ab-
normal chromosomes are considered to be stably pas-
saged to the daughter carcinoma cells. Up to now, there
have been numerous papers focusing on the role of tel-
omerase activation in the progression of cancer cells, but
the relationship between telomerase activation and drug
resistance has not yet been clearly explained.
In this study, we investigated the long-term effects of
CDDP and 5-FU, both of which are often used as anti-
cancer drugs in the actual clinical treatment of the color-
ectal cancers, on two colorectal adenocarcinoma cell
lines, LoVo and DLD-1. We cultivated these cells in the
presence of CDDP and 5-FU for more than 100 days, and
thus obtained cancer cells that were both highly resistant
to anti-cancer drugs and grew rapidly. By using these
multi-drug resistant cells, we investigated the relation-
ship among the proliferative activity, drug resistance and
telomerase-related components, including the telomere
length, telomerase activity and telomerase genes.
Materials and methods
Cell lines and culture conditions
The established human colon adenocarcinoma cell lines,
LoVo (JCRB9083) and DLD-1 (JCRB9094), were pur-
chased from Health Science Research Resources Bank.
Cells were grown in RPMI1640 medium (Iwaki, Tokyo)
containing 10% heat-inactivated fetal bovine serum (Hy-
Clone®) and anti-cancer drugs indicated as below. Fal-
con 3002 culture dishes were used for all cell passages.
Cell passages were performed when the cells reached
confluence.
Anti-cancer drugs
cis-diamminedichloroplatinum (CDDP), the DNA-in-
trastrand cross-linker, which inhibits the elongation of
the DNA chain, and 5-fluorouracil (5-FU), one of the
fluorinated pyrimidine derivatives, which inhibit thymi-
dine synthase and form abnormal RNA were used in this
study. Stock solutions of 50 µg/ml of CDDP (Wako Pure
Chemical Co., Tokyo) and 1 × 10-5 M of 5-FU (Wako)
were prepared and kept at 4°C in the dark. These drugs
were added to the culture medium at a final concentra-
tion of 0.5 µ/ml of CDDP and 1 × 10-7 M of 5-FU and then
were used for the passage. The concentration of these
drugs used in this study was the minimal dose that com-
pletely inhibits the growth of any non-resistant colorec-
tal carcinoma cells (preliminary estimated). Thereafter,
carcinoma cells were continuously grown in culture me-
dium containing these anti-cancer drugs to acquire drug
resistance. The dose indicated above was sufficient to
both induce the drug resistance and to select drug-resist-
ant cells. Anti-cancer drugs were renewed (added to the
new culture medium) at every cell passage.
Definition of the population doubling level (PDL)
After the cultured-cells reached confluence, cells were
disaggregated by trypsinization, three-fold diluted with
culture media containing anti-cancer drugs, and then re-
plated to a new culture dish. Since one PDL means dou-
bling the number of the cells as a group, the relationship
between PDL and dilution factor is defined as follows:
2n = dilution factor (where n = PDL)
If the logarithm of both sides is taken:
log2n = log(dilution factor)
Rearranging:
n (PDL) = log(dilution factor)/log2 = log(dilution fac-
tor)/0.301
Since the dilution factor in this study is 3 (three-fold di-
lution), the increase in the PDL per passage is calculated
as log3/0.301 = 0.477/0.301 = ca. 1.58
Flow cytometric analysis of the DNA histogram
Carcinoma cells at each passage stage were stored at -
80°C until the DNA histogram analysis. After all the cells
were thawed at the same time, they were used for the
DNA histogram analysis. All cells were processed by the
detergent-trypsin method according to the manufactur-
er's instructions (DNA reagent kit: CycleTEST, Becton
Dickinson). Briefly, 180 µl of 0.003 % trypsin in deter-
gent stock solution was added to the cell suspension (ca.
1 × 106 cells) and mixed gently. After 10 min of incuba-
tion at room temperature, 150 µl of the next solution (0.5
mg/ml trypsin inhibitor +0.1 mg/ml RNase A) was add-
ed. The solutions were mixed, and after 10 min at room
temperature 150 µl of an ice-cold solution of 500 µg/ml
propidium iodide (PI) was added. At 15 min after the ad-
dition of PI solution fluorescence signals were measured
with a FACSCalibur flow cytometer (Becton Dickinson)
using a 488 nm argon ion laser. To ascertain the clonality
change of the passaged cells, the fluorescence intensity of
the DNA histogram was analyzed using the CELLQuest
software package.
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The cells were plated at 5,000 cells per well in 96-well
culture plates. The cells were grown in the presence of
CDDP and 5-FU and each assay was performed in tripli-
cate. The plates were incubated at 37°C for 4 days, and
then the cell growth was measured using the Alamar blue
assay kit as previously described [12,13]. Briefly, 0.4 ml
of Alamar blue solution (Wako) was diluted to 10 ml with
phosphate buffer and mixed well. Ten µl of diluted
Alamar blue was added to each well and incubated at
37°C. After 4 h, fluorescence at 590 nm (emission wave-
length) was monitored with 560 nm excitation, and the
results were expressed as the relative intensity.
Telomere length
The telomere length was determined based on the tel-
omere restriction fragment (TRF) – Southern blot anal-
ysis as previously described [14,15]. The cells were
digested with 400 µl of DNA extraction buffer (0.25 %
NP-40, 10 µg/ml RNase I-A, 1 mM EDTA.2Na, 5 mM
Tris bolic acid [pH 8.0]) and proteinase K (1 mg/ml). Af-
ter extraction using phenol/chloroform, DNA was pre-
cipitated with ethanol and then was dissolved in distilled
water. The DNA concentration was measured, and 5 µg
of extracted DNA was digested with 10 units of HinfI
(Wako) for 1 h at 37°C. Electrophoresis of digested ge-
nomic DNA was performed in 1% agarose gel in 1 × TAE
buffer for 75 min at 50 V. After electrophoresis, the sep-
arated DNA was denatured in 0.5 M NaOH/1.5 M NaCl
at room temperature for 15 min, neutralized twice in 1 M
Tris/1.5 M NaCl (pH 7.5) at room temperature for 5 min,
and transferred to a nylon membrane (Immobilon S;
Millipore, Tokyo) using 10 × SSC by a semidry electrob-
lotter (Horizeblot, AE-6675: P/N type; ATTO, Tokyo) for
1 h. After prehybridization in hybridization buffer (1 ×
SSC, 1% milk blocking solution, 0.5% SDS solution) at
42°C for 1 h, the membrane was hybridized to a 5'-DIG
end-labeled telomeric probe (TTAGGG)4 in hybridiza-
tion buffer at 42°C for 16 h. The membrane was washed
in 1 × SSC/0.1% SDS solution and 0.1 × SSC/0.1% SDS
solution. Telomeric smears were detected by the DIG Lu-
minescent Detection Kit (Boehringer Mannheim, Tokyo)
according to the instruction manual. After color develop-
ment, the membrane image was photographed, and the
peak and mean TRF lengths were analyzed on a Macin-
tosh computer using NIH image software (version 1.60).
Telomerase activity
The telomerase activity was determined using a modi-
fied-TRAP assay [16]. This assay was performed essen-
tially as described by Kim et al. [17] with only minor
modifications. The cells were pelleted and incubated on
ice for 30 min in 200 µl of ice-cold lysis buffer (0.5%
CHAPS). The lysates were centrifuged at 16,000 g for 20
min at 4°C, and the supernatant was rapidly frozen and
stored at -80°C. The protein concentration was meas-
ured against bovine serum albumin using a Bio-Rad pro-
tein assay reagent, and an aliquot containing 0.05 µg of
protein was used. Assay tubes were prepared by seques-
tering 0.1 µg of 5'-DIG end-labeled CX primer (5'-CCCT-
TACCCTTACCCTTACCCTAA-3') under a wax barrier
(Ampliwax; Perkin Elmer Cetus, Foster City, CA, USA).
Each extract was assayed in 50 µl of reaction mixture
containing 20 mM Tris-HCl (pH 8.3), 1.5 mM MgCl2, 63
mM KCl, 0.05% Tween 20, 1 mM EGTA, 50 µM dNTPs,
0.1 µg of 5'-DIG end-labeled TS oligonucleotide (5'-
AATCCGTCGAGCAGAGTT-3') and 2 units of Taq DNA
polymerase (Boehringer Mannheim). After a 10-min in-
cubation at 23°C for telomerase-mediated extension of
the TS primer, the reaction mixture was heated and then
subjected to 31 PCR cycles at 94°C for 30 s, 50°C for 30
s, and 72°C for 90 s. The PCR product was electro-
phoresed on a 12.5% polyacrylamide gel and transferred
to a nylon membrane by a semidry electroblotter. TRAP
products were detected by the DIG Luminescent Detec-
tion Kit (Boehringer Mannheim) according to the manu-
facturer's instructions. After color development, the
membrane image was photographed and analyzed on a
Macintosh computer using NIH image software. Telom-
erase activity was evaluated by TRAP products/internal
telomerase assay standard (ITAS) ratio.
RNA extraction and quantitative reverse transcriptase 
polymerase chain reaction (RT-PCR)
The total RNA from cells was obtained using ISOGEN
(Wako), for semi-quantitative RT-PCR of drug resistance
genes (mdr-1, MRP) and telomerase component genes
(hTERT, hTR and TEP-1) according to a previously de-
scribed method [18,19]. RT-PCR was performed with to-
tal RNA (1 µg) using RNA PCR Kit (AMV) ver.2.1
(Takara, Shiga, Japan). The primers were: mdr-1, 5'-
primer nucleotide (nt) AAGCTTAGTACCAAAGAG-
GCTCTG, 3'-primer nt GGCTAGAAACAATAGT-
GAAAACAA; MRP, 5'-primer nt
TGACATTTACCTCTTCGATGAT, 3'-primer nt GTTGT-
GGTGCCTGCTGATGT; hTERT, 5'-primer nt ACTTC-
CCTGTAGAAGACGAG, 3'-primer nt
CAGAAACAGGCTGTGACACT; hTR, 5'-primer nt TC-
CCTTTATAAGCCGACTCG, 3'-primer nt GCTCTAGAAT-
GAACGGTGGA; TEP-1, 5'-primer nt
ATGCCAGCATGGATAGTGAG, 3'-primer nt AGGCTTT-
GCAT CTCTAGCAC; G3PDH, 5'-primer nt TGAAG-
GTCGGAGTCAACGGATTTGGT, 3'-primer nt
CATGTGGGCCATGAGGTCCACCAC. The thermal cycles
were: 94°C for 1 min, 57°C for 1 min (59°C for hTERT)
and 72°C for 2 min for 28 cycles for mdr-1, MRP and
G3PDH, and 30 cycles for hTERT, hTR and TEP-1. Five
µl of each PCR product was separated on a 2% agarose
gel. The gels were dyed with ethidium bromide and ex-
posed to films under UV light and the density of each
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NIH image software package. The level of expression of
mRNA was evaluated by each gene mRNA/G3PDH gene
mRNA ratio.
Statistical analysis
Differences in the means of the continuous variables be-
tween the two groups were tested by Student's t-test on a
cell proliferation assay (Fig. 2). A p value of less than
0.05 was considered to be statistically significant.
Results
Effect of long-term cultivation with anti-cancer drugs on 
the proliferative activity
LoVo and DLD-1 cells were continuously cultivated in
the presence of anti-cancer drugs (0.5 µg/ml of CDDP
and 1 × 10-7 M of 5-FU) up to 100 days, and the cell
growth was monitored. Cell proliferative activity was
evaluated based on the relationship between the number
of cultivated days and the population doubling level
(PDL) (Fig. 1). In LoVo cells, cell growth was almost com-
pletely suppressed until Day 14. First cells gradually be-
gan to proliferate (4 PDL), thereafter the growth speed
gradually increased (15 PDL) until it reached almost the
same level as that of normal control cells on Day 98 (39
PDL). Similarly, DLD-1 cells could not grow during the
first week in the presence of anti-cancer drugs. Although
the growth speed did not reach exactly the same level as
the control cells during the observation period, it
reached a level very close to that of the control cells on
Day 85 (58 PDL).
Figure 1
Relationship between culture days and population doubling
level (PDL). Colon adenocarcinoma cells (LoVo and DLD-1)
were continuously passaged in the culture medium contain-
ing 0.5 µg/ml of CDDP and 1 × 10-7 M of 5-FU. (Clear
square): control cells (without anti-cancer drugs); (Black dia-
mond): cells cultured with anti-cancer drugs (CDDP + 5-FU).
The arrows indicate 4, 15, 39 PDL in LoVo cells and 7, 27, 58
PDL in DLD-1 cells, respectively.
Figure 2
Cell proliferative activity of LoVo and DLD-1 cells cultured
with anti-cancer drugs. Cell growth activity at each passaged
stage of the cells was measured by Alamar blue assay and
expressed as relative fluorescence intensity. Each column and
bar represents mean ± SD of triplicated experiments. p val-
ues are calculated by the Student's t-test.
Figure 3
Flow cytometric analysis of the DNA histogram of the carci-
noma cells cultured with anti-cancer drugs. DNA content (PI
fluorescence intensity: FL-2 area) was expressed as a linear
scale. Median fluorescence intensity (FI), peak FI and coeffi-
cient of variation (CV) are indicated on each panel. The vari-
ation of the peak FI among each PDL was less than 3% in
LoVo cells and less than 2% in DLD-1 cells, which suggests
that no remarkable change in the chromosomal components
occurs in either cells after the passage.
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presence of anti-cancer drugs was measured by an
Alamar blue assay (Fig. 2). In the first 15 PDL, prolifera-
tive activity of LoVo cells did not show any remarkable
change compared to 0 PDL control cells. However, LoVo
cells cultured for 39 PDL with anti-cancer drugs did
show a remarkable increase in the proliferative activity
(p < 0.004 compared to 0 PDL, and p < 0.003 compared
to 15 PDL). The proliferative activity of DLD-1 cells grad-
ually increased as the PDL increased. There were signif-
icant differences between the growth capacity of 0 PDL
and 27 PDL (p < 0.04), 0 PDL and 58 PDL (p < 0.001),
and 27 PDL and 58 PDL (p < 0.02), respectively.
Effect of long-term cultivation with anti-cancer drugs on 
the clonality of the passaged cancer cells
To investigate the chromosomal stability of these pas-
saged cancer cells, a DNA histogram analysis was per-
formed by using a flow cytometer (Fig. 3). Although
special attention should be paid to the improvement of
DNA histograms quality, flow cytometry has been sug-
gested to be a reliable method for measuring the tumor
DNA content of the tumor cells [20]. As far as observing
the DNA histogram pattern of both LoVo and DLD-1 cells
at each PDL, neither an obvious appearance in the poly-
ploid nor any shift in the median/peak fluorescence in-
tensity (FI) was recognized, thus suggesting that major
chromosomal changes such as deletion and duplication
did not occur after long time cultivation of the cells with
anti-cancer drugs.
Effect of long-term cultivation with anti-cancer drugs on 
mdr-1 and MRP gene expression
The effect of passaging in the presence of anti-cancer
drugs on the expression level of mdr-1 and MRP genes
was evaluated by an RT-PCR analysis (Fig. 4). In both
cell lines, the expression level of mdr-1 and MRP genes
was upregulated after both survival and regrowth in the
anti-cancer drugs. After processing the image by NIH
software, the relative expression level of MRP and mdr-1
revealed 1.5-fold and 2.3-fold in LoVo cells at 39 PDL,
and 1.3-fold and 1.4-fold in DLD-1 cells at 58 PDL, re-
spectively. We confirmed that a simple passage of these
cells in a normal culture medium without any anti-can-
cer drugs has no effect on the expression of mdr-1 and
MRP (data not shown).
Effect of long-term cultivation with anti-cancer drugs on 
the telomere length
To investigate the effect of long-term culture with anti-
cancer drugs on the stability of chromosomes, the tel-
omere length of the genomic DNA of cultured cells was
measured by a TRF Southern blot analysis (Fig. 5). In
both cell lines, a remarkable elongation of the telomere
length was observed as the PDL increased. The Peak TRF
values of LoVo cells at 0, 15 and 39 PDL were 2.83, 4.62
and 5.48 kbp, respectively. The mean TRF values of LoVo
cells also revealed a gradual elongation as the PDL in-
creased (2.80, 4.19 and 5.28 kbp, respectively). In DLD-
1 cells the peak TRF length at 0, 27 and 58 PDL revealed
5.99, 7.96 and 9.30 kbp, and mean TRF values were 5.74,
8.67 and 8.25 kbp, respectively. Although the peak TRF
showed a continuous elongation as the PDL increased,
the mean TRF at 27 and 58 PDL were almost the same
values. Accordingly, telomere elongation may reach a
plateau in the case of DLD-1 cells.
Effect of long-term cultivation with anti-cancer drugs on 
the telomerase activity
To investigate the effect of long-term culture with anti-
cancer drugs on the telomerase activity, a modified-
TRAP assay was performed (Fig. 6). Compared with the
Figure 4
Effect of the long-term cultivation with anti-cancer drugs on
the expression of drug resistance genes. An RT-PCR analysis
of the MRP and mdr-1 genes was performed by using the
cells at each PDL. The G3PDH gene was used as an internal
control.
Figure 5
The effect of cultivation with anti-cancer drugs on the tel-
omere length. The telomere length was measured by a TRF
Southern blot analysis as described in the Materials and
Methods. Peak and mean telomere restriction fragment
(TRF) length was calculated by using an NIH image software.
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after acquiring of resistance against anti-cancer drugs in
both cell lines. In LoVo cells, the telomerase activity
reached a maximun level at 15 PDL (10.7-fold), and then
slightly decreased at 39 PDL but the activity still main-
tained at a high level (7.8-fold). The upregulation of the
telomerase activity in DLD-1 cells was also observed after
cultivation with anti-cancer drugs though the magnitude
of the increase was smaller than that in the LoVo cells.
The telomerase activity of DLD-1 cells at 7, 27 and 58
PDL was 2.0-, 3.0- and 2.8-fold, respectively and such
activities were all quite similar, in contrast to LoVo cells.
Effect of long-term cultivation with anti-cancer drugs on 
hTERT, hTR and TEP-1 expression
To analyze the telomerase activation on the gene level,
the mRNA expression of three major gene components
of the telomerase, hTERT, hTR and TEP-1, in the passag-
es cells was observed (Fig. 7). The mRNA expression of
hTERT and hTR was upregulated after acquiring resist-
ance against anti-cancer drugs and the time course was
similar to that of the telomerase activity. Both hTERT
mRNA and hTR mRNA reached a maximum level at 15
PDL in LoVo cells and at 27 PDL in DLD-1 cells, respec-
tively. Although an upregulation of TEP-1 mRNA was
also observed, the increase was not significant compared
to that of hTERT and hTR.
Discussion
In this paper we investigated the role of the telomere
length and telomerase activity during the acquisition of
multidrug resistance in two colorectal carcinoma cell
lines, LoVo cells and DLD-1 cells. When the cells were
cultured with anti-cancer drugs, CDDP and 5-FU, cell
growth was strongly suppressed during the first several
PDL. Thereafter, the growth speed gradually increased
and reached almost the same level as the control cells at
98 days (39 PDL) in LoVo cells and 85 days (58 PDL) in
DLD-1 cells (Fig. 1). As the carcinoma cells acquired drug
resistance, the cell growth accelerated significantly (Fig.
2). In this situation, the telomere length in both cell lines
elongated considerably as the PDL increased (Fig. 5).
During the process of telomere elongation, the telomer-
ase activity was strongly upregulated, and then slightly
decreased thereafter (Fig. 6). Since we did not perform
any experiments regarding the single use of each agent,
no conclusions based on the single use of each agent can
be made. However, our present study is considered to
represent the synergistic effect of these two drugs. It is
commonly believed that activation of telomerase in colon
cancer occurs during the process of extensive telomere
shortening and oncogenesis. In addition, the telomerase-
induced stabilization of telomeres may be essential for
the continued proliferation of malignant clones [21]. In
our study, telomerase was remarkably upregulated in the
cells that acquired drug resistance and active cell prolif-
erative potential. An elongation of the telomeres in both
LoVo and DLD-1 cells may be supported by the high tel-
omerase activity.
Figure 6
The effect of the long-term culture with anti-cancer drugs on
the telomerase activity. The telomerase activity was
observed by a modified-TRAP assay. Top: A ladder pattern
after acrylamide gel electrophoresis. Bottom: the band inten-
sity was measured using an NIH-Image software package and
telomerase activity (TA: band intensity of the TRAP prod-
ucts/band intensity of the ITAS) was also calculated. Thereaf-
ter, the TA was converted to the relative value (TA at 0 PDL
= 1.0). All experiments were repeated at least three times
and representative results are shown in this figure.
Figure 7
Effect of long-term culture with anti-cancer drugs on the
mRNA expression of the three major gene components of
telomerase, hTERT, hTR and TEP-1. An RT-PCR analysis of
the hTERT, hTR and TEP-1 genes was performed by using
the cells at each PDL. The G3PDH gene was used as an inter-
nal control.
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exists between the telomerase activity and telomere
length in malignant tumor cells, and the levels of the tel-
omerase components or telomerase activity are not pre-
dictive of the telomere length. Our finding that the
telomere length was continuously elongated in both cell
lines after incubation with anti-cancer drugs cannot be
fully explained by increased telomerase activity because
the increased telomerase activity reaches its peak at 15
PDL in LoVo cells and 27 PDL in DLD-1 cells, respective-
ly. Thereafter, the level of telomerase activity decreased.
The same tendency was also observed with levels of
hTERT hTR and TEP-1. One probable interpretation for
the telomere data is that anti-cancer drugs killed cells
with short telomeres, thus resulting in the selective sur-
vival of cells with longer telomeres. Another explanation
could be due to the involvement of an alternative length-
ening of the telomeres (ALT) mechanism [22,23], which
may play some role in the phase of low telomerase activ-
ity, although the precise mechanism is still unclear.
These conclusions may differ from those in which there
is active telomere elongation via an upregulation of the
telomerase activity. However, it is also possible that the
cells which possess a high telomerase activity and longer
telomere were selected in the process of acquisition of
multidrug resistance. Savre-Train et al. reported that
clonal heterogeneity in telomerase activity and telomere
length was observed in tumor-derived cell lines [24]. In
their study, critically short telomeres in tumor-derived
cell lines may upregulate the telomerase activity through
an increase in the expression of the catalytic submit of te-
lomerase. Although clones with a low telomerase activity
shorten their telomeres over time, their subclones all
have high levels of telomerase activity with no telomere
shortening. In addition, there may also be fluctuation of
activity levels in individual cells. Moreover, Kiyozuka et
al. reported that the ovarian cancer cells with longer TRF
and higher steady-state hTR expression showed signifi-
cantly less sensitivity to CDDP [9]. These results support
the hypothesis that the telomerase activity was upregu-
lated and carcinoma cells possessing longer telomere
may be selected during long-term cultivation with anti-
cancer drugs. Actually in our study an increased expres-
sion of telomerase genes especially in hTERT, a catalytic
component of the telomerase, was observed in the step of
acquiring a growth advantage (Fig. 7).
The telomere length of HeLa cells treated with CDDP has
been shown to become shortened after 24 to 72 hr [25].
In addition, Burger et al. demonstrated that CDDP re-
duced telomerase activity of human testicular tumor
cells in a specific and concentration-dependent manner
within 4 hr after treatment [26]. However, there have
been no reports showing the change in the telomerase
activity and telomere length of long-term cultured cancer
cells in the presence of anti-cancer drugs. This is the first
report describing the relationship between drug resist-
ance and the elongation of telomeres. Regarding the re-
lationship between drug resistance and telomerase
activity, there is still no clear explanation. Terashima et
al. reported the importance of a telomerase assay as a
possible predictor of the response to anti-cancer chemo-
therapy by using several human gastric and breast can-
cer cells [26]. In their experiments, the telomerase
activity correlated significantly with the number of viable
cells, and after drug exposure the activity decreased rap-
idly in a dose dependent fashion. We observed a very low
level of telomerase activity during the first several PDL in
both LoVo and DLD-1 cell lines (data not shown; we con-
firmed this result by ELISA-based TRAP assay because
we could not obtain a sufficient number of cells for the
analysis due to the very slow proliferation speed around
these PDL), and this also closely correlated with their re-
sults. However, in our study, as the PDL progressed, the
cells regained their growth activity and this was also as-
sociated with a high level of telomerase activity. Ishikawa
et al. reported similar results using MCF-7 breast carci-
noma cells [27]. In the control cells, the telomerase activ-
ity decreased significantly due to the anti-cancer drug
treatments; whereas in adriamycin-resistant cells, adri-
amycin significantly increased the enzyme activity while
other drugs reduced enzyme activity. They thus conclud-
ed that an unusual reaction of telomerase activity might
explain, at least in part, one of the mechanisms of the
malignant biological behavior related with the drug re-
sistance to adriamycin. During the process of acquiring
drug resistance two quite different phases seem to exist
regarding the telomerase activity, the former is a sup-
pressive phase and the latter is a phase of upregulation.
Therefore, telomere elongation may be the result of up-
regulated telomerase activity in the drug resistant cells.
In our experiments, no obvious chromosomal changes
(i.e. change in the DNA content) were not detected after
long-term cultivation with anti-cancer drugs as far as
could be observed on the DNA histogram level (Fig. 3).
Since we did not perform a precise chromosome analy-
sis, we can not completely rule out the possibility that te-
lomere elongation is due to the appearance of an
abnormal clone and the subsequent selection of this
clone. However, the upregulation of the telomerase ac-
tivity and the subsequent elongation of the telomeres
may contribute to the drug resistance of colorectal carci-
noma cells.
Conclusions
Taken together we conclude that the selection of the tu-
mor cells that possess a strong resistance to anti-cancer
drugs may occur in the process of long-term cultivation
with anti-cancer drugs. It is also suggested that cancer
cells with long telomeres and a high proliferative activity
BMC Cancer (2001) 1:10 http://www.biomedcentral.com/1471-2407/1/10help such cells between survive under the anti-cancer
drugs, presumably due to increased chromosome stabil-
ity and strong expression of mdr-1 and MRP genes.
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